Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease.
about
Amyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent mannerRole of cyclic nucleotide-gated channels in the modulation of mouse hippocampal neurogenesisDesign and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy.Synaptic therapy in Alzheimer's disease: a CREB-centric approach.Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia.Nitric oxide and geriatrics: Implications in diagnostics and treatment of the elderly.Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents.Soluble beta amyloid evokes alteration in brain norepinephrine levels: role of nitric oxide and interleukin-1.Impairments in fear conditioning in mice lacking the nNOS geneRole of phosphodiesterase 5 in synaptic plasticity and memoryRegulation of IL-1β-induced cyclooxygenase-2 expression by interactions of Aβ peptide, apolipoprotein E and nitric oxide in human neuroglioma.Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity.Pharmacological modulators of nitric oxide signaling and contextual fear conditioning in mice.Role of the NMDA receptor and nitric oxide in memory reconsolidation of cocaine-induced conditioned place preference in mice.Differential role of the nNOS gene in the development of behavioral sensitization to cocaine in adolescent and adult B6;129S mice.Regucalcin confers resistance to amyloid-β toxicity in neuronally differentiated PC12 cells.
P2860
Q28476620-B7C78C03-EAD0-4E35-94A5-FBC3D14BF97CQ31133608-9AA5221F-DF35-4AED-8F49-608EEB0B7CA3Q34332249-FC046EB2-EBFD-4311-A3D0-28EBA201F2C9Q35064948-2D1CD7CE-8CF7-464D-8E23-980B63F0049EQ35813037-D345169D-0293-4250-B071-2EC66FA825DCQ36077331-FA72B3D9-E0A6-4EA8-9FD0-5621DC2EB329Q36124990-EE280219-3004-41C2-8DC5-92CE6CB0A5D2Q36249492-C80307D1-1538-4241-A8F0-6E1F485B0A97Q37246165-3DDA10B3-12B7-4B1E-881F-3295669EA61BQ37252748-073B4FE0-7C83-4658-9B03-802F07E258FBQ39439875-D28979B1-5493-4A1F-8CE0-0F780EA85FD2Q39743698-E1DB7E55-0887-487F-A948-8574C6A4E9B2Q43132159-9DD9261C-4B74-4DEE-9C67-899D98D794D1Q46258401-8217584B-7BF3-4DEA-B404-75E9649E3115Q46508796-8609890F-423F-43AB-8DDD-CF4BB58A9151Q52689210-440E4359-DA58-41E0-B550-2D858843299B
P2860
Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Involvement of the nitric oxid ...... vation in Alzheimer's disease.
@ast
Involvement of the nitric oxid ...... vation in Alzheimer's disease.
@en
type
label
Involvement of the nitric oxid ...... vation in Alzheimer's disease.
@ast
Involvement of the nitric oxid ...... vation in Alzheimer's disease.
@en
prefLabel
Involvement of the nitric oxid ...... vation in Alzheimer's disease.
@ast
Involvement of the nitric oxid ...... vation in Alzheimer's disease.
@en
P2860
P50
P1476
Involvement of the nitric oxid ...... vation in Alzheimer's disease.
@en
P2860
P304
P356
10.1515/REVNEURO.2006.17.5.497
P577
2006-01-01T00:00:00Z